New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
2014 Healthcare Conference to be held in Boston on June 17-18.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 27, 2015
09:38 EDTISISIsis Pharmaceuticals sees FY15 pro forma NOL in mid-$50M range
Sees ending FY15 with more than $630M in cash, representing net cash outflows of only $100M to move forward its pipeline.
09:34 EDTISISIsis Pharmaceuticals reports Q4 EPS 25c, consensus 2c
Subscribe for More Information
February 26, 2015
18:43 EDTKNDOn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTKNDKindred Healthcare reports Q4 EPS 26c, consensus 26c
Reports Q4 revenue $1.26B, consensus $1.27B.
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
11:11 EDTMRGEMerge Healthcare falls after revenue misses, acquisition made
Shares of Merge Healthcare (MRGE) are falling this morning after the company reported its fourth quarter results last night and also disclosed its deal to acquire a privately-held medical imaging information systems company. WHAT'S NEW: Last night, Merge reported Q4 pro forma revenue of $53.7M, which was below the $56.4M consensus expectation, and adjusted earnings per share of 5c, which was a penny above the 4c consensus forecast. The company also announced the recent acquisition of DR Systems for $70M. The transaction is expected to be accretive to Merge's non-GAAP adjusted EPS in 2015 and future years, the company said. ANALYST OPINION: IN a note to investors after the quarterly report, William Blair said it was disappointed that Merge did not provide 2015 guidance or end-of-year backlog results. The firm believes the larger footprint from the DR Systems deal will benefit the company’s cloud strategy and that DR's highly-ranked products should increase mindshare, but noted that it awaits commentary on the company’s organic growth outlook to fully evaluate the deal. The firm has a Market Perform rating on Merge Healthcare shares. PRICE ACTION: In morning trading, shares of Merge Healthcare are down 65c, or 14.4%, to $3.85.
February 25, 2015
18:11 EDTMRGEMerge Healthcare acquires DR Systems
Merge Healthcare acquired DR Systems, a privately held San Diego-based medical imaging information systems company. DR Systems founder, chairman, and CEO Murray Reicher, M.D., will assume the role of Chief Medical Officer of Merge Healthcare. Dr. Following the acquisition, support for DR Systems' core platform will remain in place. The transaction is expected to be accretive to Merge's adjusted EPS in 2015 and future years. Merge Healthcare financed the acquisition through a combination of approximately $20M of cash on hand and $50M of cash raised from the sale of shares of newly issued convertible preferred stock, at a $4.14 per share common equivalent calculated based on Merge's 30-day volume weighted average common stock price, to a group of investors arranged by Guggenheim Corporate Funding, the agent under Merge's existing credit facility.
16:22 EDTGMEDGlobus Medical enters agreement to acquire Branch Medical Group
Subscribe for More Information
16:21 EDTGMEDGlobus Medical backs FY15 EPS view about $1.01, consensus $1.02
Backs FY15 revenue view about $510M, consensus $512.92M.
16:20 EDTGMEDGlobus Medical reports Q4 adjusted EPS 30c, consensus 25c
Subscribe for More Information
February 24, 2015
13:23 EDTCVSLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
February 23, 2015
18:02 EDTDEPOOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTDEPODepomed sees 2015 product sales $152M-$162M
Subscribe for More Information
16:06 EDTDEPODepomed reports Q4 adjusted EPS 21c, consensus 7c
Subscribe for More Information
09:02 EDTBDSIAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTBDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
07:22 EDTISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
08:21 EDTBDSISummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use